Cargando…

Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide

BACKGROUND: Sandostatin(® )LAR(® )(Novartis Pharma AG) is a long-acting repeatable formulation of the somatostatin analogue octreotide, the safety and efficacy of which has been established through 15 years of clinical experience. Recently, other formulations of octreotide using polymer poly(lactic-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petersen, Holger, Bizec, Jean-Claude, Schuetz, Helmut, Delporte, Marie-Laure
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212992/ https://www.ncbi.nlm.nih.gov/pubmed/21906300 http://dx.doi.org/10.1186/1756-0500-4-344

Ejemplares similares

A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas
por: Hrachova, Maya, et al.
Publicado: (2020)

The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and hepatic blood flow in an experimental model of hepatic metastases.
por: Hemingway, D. M., et al.
Publicado: (1992)

Everolimus in combination with octreotide LAR in thymic atypical carcinoid
por: Sakane, Tadashi, et al.
Publicado: (2023)

Sandostatin therapy in patients with chronic sarcoidosis
por: Timmermans, Wilhelmina M.C., et al.
Publicado: (2017)

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)

SAT-432 MTD201 Has a Favourable 28-Day Sustained Release Profile Compared to Sandostatin LAR in Healthy Subjects
por: Seaman, Paul, et al.
Publicado: (2019)

Population Pharmacokinetic Modelling of the Complex Release Kinetics of Octreotide LAR: Defining Sub-Populations by Cluster Analysis
por: Kapralos, Iasonas, et al.
Publicado: (2021)

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
por: Tiberg, Fredrik, et al.
Publicado: (2015)

Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension
por: Cui, Pei-Jing, et al.
Publicado: (2017)

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011)

Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin.
por: Nelson, J., et al.
Publicado: (1989)

Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2016)

Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR
por: Yanagisawa, Asako, et al.
Publicado: (2017)

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis
por: Ryan, P, et al.
Publicado: (2019)

Octreotida (sandostatin) mas tratamiento convencional en la diarrea refractaria del SIDA.
por: Rosado Castellanos, Marcos Antonio
Publicado: (1995)

Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea
por: Chin, Sang Ouk, et al.
Publicado: (2015)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR
por: Porto, Lara Benigno, et al.
Publicado: (2018)

Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
por: Caraglia, M, et al.
Publicado: (2011)

Uneventful octreotide LAR therapy throughout three pregnancies, with favorable delivery and anthropometric measures for each newborn: a case report
por: Naccache, Deeb Daoud, et al.
Publicado: (2011)

Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour
por: Abell, Sally K, et al.
Publicado: (2015)

Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study
por: Kirzinger, Lukas, et al.
Publicado: (2016)

SAT-435 Optimization of Pharmacological Treatment of Acromegaly: Impact on IGF-1 Levels Comparing Isolated Octreotide LAR and Combined Pharmacological Therapy
por: Naves, Luciana, et al.
Publicado: (2019)

Amelioration of Symptoms and Reduction of VIP Levels after Hepatic Artery Chemoembolization in a Patient with Sandostatin Resistant VIPoma
por: Shaib, Walid, et al.
Publicado: (2010)

Preparation of long-acting microspheres loaded with octreotide for the treatment of portal hypertensive
por: Han, Bing, et al.
Publicado: (2021)

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
por: Perico, Norberto, et al.
Publicado: (2019)

Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
por: Gutiérrez, Lilia, et al.
Publicado: (2012)

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
por: Klijn, J. G., et al.
Publicado: (1990)

Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation
por: Helland, Arne, et al.
Publicado: (2017)

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives
por: Yau, Hanford, et al.
Publicado: (2017)

Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
por: Yoon, Seonghae, et al.
Publicado: (2014)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
por: Wolin, Edward M., et al.
Publicado: (2013)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Prolonged progression‐free survival achieved by octreotide LAR plus transarterial embolization in low‐to‐intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden
por: Liu, Yiming, et al.
Publicado: (2022)

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012)

Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors
por: Cheng, Yue, et al.
Publicado: (2023)

Octreotide and hepatocellular carcinoma
por: Farinati, F, et al.
Publicado: (2007)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016)

Comparative Study on Pharmacokinetics of Four Long-Acting Injectable Formulations of Enrofloxacin in Pigs
por: Ahmad, Salah Uddin, et al.
Publicado: (2021)

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions
por: Hövelmann, Ulrike, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vme0l1aernip98ics8e10av5lg